SOLICITATION NOTICE
A -- Synthesis of dimethylmorpholino
- Notice Date
- 2/1/2011
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HG)-2011-088-DLM
- Archive Date
- 2/22/2011
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) intends to negotiate and award a purchase order on a noncompetitive sole source basis to AA Pharmaceuticals, 470 Wildwood Avenue, Suite 3, Woburn, Massachusetts 01801-2082 for the synthesis of 10 g of 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl) acetamide (KU-660019). The sole source determination is based on the fact that National Institute of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency conducting and supporting making medical discoveries that improve people’s health and save lives. The NIH Chemical Genomics Center (NCGC) of the National Human Genome Research Institute (NHGRI) has several active internal neurodegeneration programs looking for small molecules which can have a therpeutical effect in the neurodegeneration animal model. NCGC is collaborating with UCLA Medical School as part of their internal neurodegeneration projects. Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases including Parkinson’s, Alzheimer’s, and Huntington’s occur as a result of neurodegenerative processes. As research progresses, many similarities appear which relate these diseases to one another on a sub-cellular level. Discovering these similarities offers hope for therapeutic advances that could ameliorate many diseases simultaneously. There are many parallels between different neurodegenerative disorders including atypical protein assemblies as well as induced cell death. Neurodegeneration can be found in many different levels of neuronal circuitry ranging from molecular to systemic. Currently there is no effective cure for a number of neurodegeneration diseases. In an initial evaluation already conducted 250 mg of compound has already been synthesized, however, for a long term neurodegeneration disease study (animals will be treated for at least five months), NCGC will need to produce 10 grams of this compound. Therefore, this requirement is to procure 10 g of 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl) acetamide (KU-660019). AA Pharmaceuticals Inc. has experience for custom synthesizing this compound in the past and has all the needed infrastructure to do this work. Additionally, AA Pharmaceuticals Inc. has the expertise and knowledge of NHGRI and specifically the research need for the NIH Chemical Genomics Center. The Contractor: • The Contractor will deliver 10g of 2-((2S, 6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide (KU-660019) according to the synthetic schemes provided by NCGC scientists with an estimated timeline of 10-12 weeks. • The Contractor will report the progress of synthesis every week to NCGC by e-mail or teleconference, and discuss questions and problems in a timely manner. The final 10 grams of KU-66019 submitted to NCGC will have LC-MS and NMR spectrum data. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology, with size standard of 500 employees, this is a small business set-aside. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001).and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-49 (January 24, 2011). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by February 7, 2011, 7:30 a.m. Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HG)-2011-088-DLM, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HG)-2011-088-DLM/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02370769-W 20110203/110201234224-df25593580c96aebdbd6667db526f5bd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |